Program
BGM1812
A development code. Also written as “BGM1812 injection / plcaebo”.
Its studies are mostly in Obesity · Overweight, led by BrightGene Bio-Medical Technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| BrightGene Bio-Medical Technology | 31 open or running | phase 2since Oct 30, 2026 | Oct 29, 2025 | Aug 1, 2027phase 2 · NCT07918625 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 29, 2025First study: phase 1 study in OverweightFirst studyNCT07224399 · 60 enrolled · United States
- Dec 7, 2025Phase 1 study in OverweightNCT07294235 · 60 enrolled · China
- Oct 30, 2026Phase 2 study in OverweightPhase 2 reachedNCT07918625 · 160 planned · China
Ahead
- Aug 1, 2027Primary completion: phase 2 study in OverweightNCT07918625
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07918625Overweight · China | 2 | Not yet recruiting | Aug 1, 2027 | 160 |
| NCT07294235Overweight · China | 1 | Completed | Jun 5, 2026 | 60 |
| NCT07224399Overweight · United States | 1 | Completed | Jul 17, 2026 | 60 |
How it is read
Names in the registry
- “BGM1812”, 4 entries
- “BGM1812 injection / plcaebo”, 4 entries
Codes read as this program: BGM1812.
Conditions, from the studies’ own filings
- Obesity, 2 studies
- Overweight, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.